TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10812221

Group type: EXPERIMENTAL
Intervention: Priorix (new MMR vaccine)
Number of subjects: 1779

Group type: COMPARATOR
Intervention: Triviraten (widely used MMR vaccine)
Number of subjects: 1779
Study: 8888864

Group type: COMPARATOR
Intervention: Window size of 4-5 characters for normally sighted (NA) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Window size of 6-7 characters for visually impaired (VI) group
Number of subjects: 0
Study: 1893310

Group type: EXPERIMENTAL
Intervention: Computer-managed instruction (faculty as tutors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional classroom course of study
Number of subjects: 0
Study: 6298103

Group type: EXPERIMENTAL
Intervention: MK-421
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30948273

Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg once daily continuously
Number of subjects: 463
Study: 30241559

Group type: EXPERIMENTAL
Intervention: Pre-prepared PHEA equipment and drugs
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 23
Study: 26998697

Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24481640

Group type: EXPERIMENTAL
Intervention: i-CEOP (intensive chemotherapy): cyclophosphamide 1,500 mg, epirubicin 150 mg, vincristine 1.4 mg/m2, prednisolone 100 mg days 1-5
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: i-CEOP (intensive chemotherapy)
Number of subjects: 250

Group type: COMPARATOR
Intervention: s-CEOP (standard chemotherapy): cyclophosphamide 750 mg, epirubicin 75 mg, vincristine 1.4 mg/m2, prednisolone 100 mg days 1-5
Number of subjects: 250

Group type: COMPARATOR
Intervention: s-CEOP (standard chemotherapy)
Number of subjects: 250
Study: 22205319

Group type: EXPERIMENTAL
Intervention: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control diet (0.9 g/d, 0.3% of daily energy)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy) among women with BMI ≥25
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy) among women with BMI <25
Number of subjects: 61
Study: 19041207

Group type: EXPERIMENTAL
Intervention: MR colonography (MRC) with fecal tagging
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MR colonography (MRC) with bowel purgation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Discomfort with contrast mixture
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Discomfort with bowel purgation
Number of subjects: 64
Study: 17726919

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)
Number of subjects: 0
Study: 15629822

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (IOL)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL
Number of subjects: 106
Study: 12197367

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 501

Group type: COMPARATOR
Intervention: CEE-MPA (conjugated equine oestrogens 0.625 mg + medroxyprogesterone acetate 5 mg)
Number of subjects: 501
Study: 10534591

Group type: EXPERIMENTAL
Intervention: COOP charts
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 129
Study: 7781462

Group type: EXPERIMENTAL
Intervention: 200 mg/kg/hr L-arginine
Number of subjects: 21

Group type: COMPARATOR
Intervention: 2 mg/kg erythromycin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Liquid meal
Number of subjects: 21
Study: 2180492

Group type: EXPERIMENTAL
Intervention: Chlorambucil at a daily dose of 0.1 mg/kg
Number of subjects: 612

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Stage A patients with hemoglobin ≥ 120 g/L and lymphocyte count < 30 x 10(9)/L
Number of subjects: 612
Study: 6997218

Group type: EXPERIMENTAL
Intervention: Post-dilution hemofiltration
Number of subjects: 14
Study: 31200160

Group type: EXPERIMENTAL
Intervention: Real indoor air purification (PM2.5 exposure reduced to 28.3 μg/m3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham indoor air purification (PM2.5 exposure at 56.9 μg/m3)
Number of subjects: 45
Study: 28609276

Group type: EXPERIMENTAL
Intervention: Social oocyte cryopreservation
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Cost barrier to oocyte cryopreservation
Number of subjects: 379
Study: 26272704

Group type: EXPERIMENTAL
Intervention: Single-visit treatment
Number of subjects: 538

Group type: COMPARATOR
Intervention: Multiple-visit treatment
Number of subjects: 538
Study: 23808447

Group type: EXPERIMENTAL
Intervention: Nutritional traffic light system (S-SN)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Monochrome system (SM)
Number of subjects: 32
Study: 21509668

Group type: EXPERIMENTAL
Intervention: Hongyou Ointment and Shengji Powder (CM group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Mupirocin ointment, growth factor (bFGF), and Vaseline gauze (WM group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CM treatment
Number of subjects: 62
Study: 19453580

Group type: EXPERIMENTAL
Intervention: New landmark-guided approach
Number of subjects: 140

Group type: COMPARATOR
Intervention: Traditional para-carotid approach
Number of subjects: 140
Study: 16541934

Group type: EXPERIMENTAL
Intervention: Caloric asymmetry
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Higher age
Number of subjects: 54
Study: 15189627

Group type: EXPERIMENTAL
Intervention: Emotional support provided by women
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Agency
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Unmitigated communion
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Negative interactions
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Advice
Number of subjects: 79
Study: 11112243

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg (two 500-mg Extra Strength Tylenol tablets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9167744

Group type: EXPERIMENTAL
Intervention: Angiotensin II (AT II) infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline (without AT II infusion)
Number of subjects: 11
Study: 8460050

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg p.o. HS on postoperative days 1, 2, and 3
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3079935

Group type: EXPERIMENTAL
Intervention: 1 mg/day leuprolide acetate
Number of subjects: 199

Group type: COMPARATOR
Intervention: 3 mg/day diethylstilbestrol (DES)
Number of subjects: 199
Study: 28695457

Group type: EXPERIMENTAL
Intervention: Preoperative C-peptide testing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fasting and stimulated C-peptide measurements
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Islet cell antibody testing
Number of subjects: 12
Study: 27335114

Group type: EXPERIMENTAL
Intervention: Brivaracetam 50 mg/d
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg/d
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Brivaracetam 200 mg/d
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study: 24947633

Group type: EXPERIMENTAL
Intervention: Closure of the hernia gap during laparoscopic ventral hernia repair
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard laparoscopic ventral hernia repair (non-closure of the gap)
Number of subjects: 80
Study: 22079507

Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 20731495

Group type: EXPERIMENTAL
Intervention: Oregon model of Parent Management Training (PMTO)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-intervention condition
Number of subjects: 110
Study: 18685503

Group type: EXPERIMENTAL
Intervention: Symbiotic formulation (Flortec)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Prebiotic
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Symbiotic formulation (Flortec) in IBS-predominant diarrhea
Number of subjects: 267
Study: 16549835

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/d for 6 weeks, then 10 mg/d for 18 weeks
Number of subjects: 34
Study: 15023160

Group type: EXPERIMENTAL
Intervention: MMF/CNI continuation
Number of subjects: 39

Group type: COMPARATOR
Intervention: MMF/CNI withdrawal
Number of subjects: 39
Study: 11697809

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9386022

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 59
Study: 8204703

Group type: EXPERIMENTAL
Intervention: UDCA 10 mg/kg/day for one year
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: UDCA continued for three further months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo after 12 months of UDCA
Number of subjects: 90
Study: 3301452

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol, 160 mg once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional propranolol, 40 mg three times daily
Number of subjects: 19
Study: 29941495

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) 4,000 IU daily
Number of subjects: 2423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2423
Study: 26678311

Group type: EXPERIMENTAL
Intervention: Low-dose bexarotene plus PUVA
Number of subjects: 21
Study: 23989505

Group type: EXPERIMENTAL
Intervention: Dental care program (complimentary care before and during oncological therapy)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Basic dental care (Control Group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dental care program (TG)
Number of subjects: 46
Study: 23838777

Group type: EXPERIMENTAL
Intervention: Heptavalent vaccine
Number of subjects: 421

Group type: COMPARATOR
Intervention: Comparator vaccines
Number of subjects: 421
Study: 21223755

Group type: EXPERIMENTAL
Intervention: Taxol plus Carboplatin (TP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Gemcitabine plus Carboplatin (GP)
Number of subjects: 86
Study: 18467717

Group type: EXPERIMENTAL
Intervention: Faxed patient/regimen-specific information
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual correspondence
Number of subjects: 97
Study: 17010792

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose
Number of subjects: 292

Group type: COMPARATOR
Intervention: 300 mg clopidogrel loading dose
Number of subjects: 292
Study: 14613088

Group type: EXPERIMENTAL
Intervention: Model surgery performed with the aid of a robot arm
Number of subjects: 21

Group type: COMPARATOR
Intervention: Manual model surgery
Number of subjects: 21
Study: 11092418

Group type: EXPERIMENTAL
Intervention: Sexually stimulating primes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral stimuli
Number of subjects: 0
Study: 8831315

Group type: EXPERIMENTAL
Intervention: Cold saline‐induced paresthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nerve stimulator
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 1389822

Group type: EXPERIMENTAL
Intervention: methohexitone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: propofol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: thiopentone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 96
Study: 4025156

Group type: EXPERIMENTAL
Intervention: Low-dose infusion of amrinone (200 micrograms/kg/hr for 30 minutes, 400 micrograms/kg/hr for 30 minutes and then 800 micrograms/kg/hr for 30 minutes)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-dose infusion of amrinone (800, 1,600 and 3,200 micrograms/kg/hr sequentially, each for 30 minutes)
Number of subjects: 22
Study: 30180806

Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment for 7 days
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo treatment for 7 days
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment for 7 days in hyponatremia patients with resolved serum sodium
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment for 7 days in hyponatremia patients with unresolved serum sodium
Number of subjects: 249
Study: 24906836

Group type: EXPERIMENTAL
Intervention: Ayurvedic drugs (Mauktikyukta Kamdudha and Mauktikyukta Praval Panchamruta) during chemotherapy (Arm 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ayurvedic drugs (Mauktikyukta Kamdudha and Mauktikyukta Praval Panchamruta) after chemotherapy (Arm 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Suvarnabhasmadi formulation in addition to MKD and MPP after chemotherapy (Arm 3)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control group)
Number of subjects: 48
Study: 22241101

Group type: EXPERIMENTAL
Intervention: Pre-visit website with question prompt sheet (QPS)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 192
Study: 20334478

Group type: EXPERIMENTAL
Intervention: Erdosteine (triple therapy consisting of pantoprazole, amoxicillin, and clarithromycin plus erdosteine)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (triple therapy plus placebo)
Number of subjects: 79
Study: 18361800

Group type: EXPERIMENTAL
Intervention: Aprotinin (500,000 IU after induction and repeat dose after chest closure)
Number of subjects: 59
Study: 16418548

Group type: EXPERIMENTAL
Intervention: Foot reflexology (60 minutes, twice a week for five weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 59
Study: 12917184

Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 419

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Patching (10 or more hours a day)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Patching (less than 10 hours a day)
Number of subjects: 419
Study: 10417464

Group type: EXPERIMENTAL
Intervention: suxamethonium 0.1 mg.kg‐1 intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (placebo)
Number of subjects: 60
Study: 7473009

Group type: COMPARATOR
Intervention: Surgical debridement alone (DEBR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ePTFE membrane alone (G)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ePTFE membrane plus root conditioning (G + D)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ePTFE membrane plus root conditioning plus composite graft (G + D + B)
Number of subjects: 7
Study: 1814457

Group type: EXPERIMENTAL
Intervention: Silver amalgam products (six different gamma‐2‐free types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copalite
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High copper content silver amalgam products
Number of subjects: 0
Study: 7053030

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 30819711

Group type: EXPERIMENTAL
Intervention: RT + HMB
Number of subjects: 156

Group type: COMPARATOR
Intervention: RT + placebo
Number of subjects: 156

Group type: COMPARATOR
Intervention: education + HMB
Number of subjects: 156

Group type: COMPARATOR
Intervention: education + placebo
Number of subjects: 156
Study: 27484436

Group type: EXPERIMENTAL
Intervention: Concurrent treatment with vitamin K2 (45 mg/day) and risedronate (2.5 mg/day or 17.5 mg/week)
Number of subjects: 1874

Group type: COMPARATOR
Intervention: Risedronate (2.5 mg/day or 17.5 mg/week) alone
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Concurrent treatment with vitamin K2 and risedronate
Number of subjects: 1874

Group type: COMPARATOR
Intervention: Risedronate alone
Number of subjects: 1874
Study: 25727583

Group type: EXPERIMENTAL
Intervention: Web-based vision screening test (WBT) VisionForKids.org
Number of subjects: 203

Group type: COMPARATOR
Intervention: Electronic Visual Acuity (EVA) Tester
Number of subjects: 203
Study: 24263075

Group type: EXPERIMENTAL
Intervention: 1‐legged helium‐hyperoxia (1L‐HH)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1‐legged nitrogen‐hyperoxia (1L‐NH)
Number of subjects: 15
Study: 22534814

Group type: EXPERIMENTAL
Intervention: Pralatrexate 190 mg/m on days 1 and 15 of a 28-day cycle
Number of subjects: 201

Group type: COMPARATOR
Intervention: Erlotinib 150 mg/day
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Pralatrexate
Number of subjects: 201
Study: 19173756

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 0
Study: 17293707

Group type: EXPERIMENTAL
Intervention: Quetiapine addition to serotonin reuptake inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15223203

Group type: EXPERIMENTAL
Intervention: Cold pressor test condition (high-hostile men)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-cold pressor test condition (low-hostile men)
Number of subjects: 56
Study: 11453610

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled beta agonists, theophylline, cromolyn, inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 0
Study: 10938493

Group type: EXPERIMENTAL
Intervention: High-dose furosemide (500-1000 mg) plus hypertonic saline solution (HSS) infusion (150 ml of 1.4-4.6% NaCl) b.i.d.
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-dose furosemide (500-1000 mg) as a bolus b.i.d. without HSS.
Number of subjects: 60
Study: 8794422

Group type: EXPERIMENTAL
Intervention: Matrix transdermal estradiol delivery system worn for 7 consecutive days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Reservoir transdermal patch worn for 4 days followed by another patch for 3 days
Number of subjects: 26
Study: 1536785

Group type: EXPERIMENTAL
Intervention: 5% 5-aminosalicylic acid (5-ASA) cream applied three times daily for up to 14 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo applied three times daily for up to 14 days
Number of subjects: 22
Study: 6391735

Group type: EXPERIMENTAL
Intervention: Oral mixed grass‐pollen vaccine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 54
Study: 30895694

Group type: EXPERIMENTAL
Intervention: Purslane seeds (10 g/day) with low-calorie diet
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low-calorie diet
Number of subjects: 54
Study: 29698955

Group type: EXPERIMENTAL
Intervention: Lower serum uromodulin (tertile 1)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Lower serum uromodulin (tertile 1) after adjustment for confounding factors
Number of subjects: 613
Study: 27423791

Group type: EXPERIMENTAL
Intervention: Multidisciplinary supportive program (3-month duration, including three 60-min group classes, three 30-min peer support groups, and regular telephone follow-ups)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 118
Study: 24799118

Group type: EXPERIMENTAL
Intervention: LED thermocured HVGIC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glass-carbomer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional HVGIC
Number of subjects: 0
Study: 22672949

Group type: EXPERIMENTAL
Intervention: Positional Release Therapy (PRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine medical therapy
Number of subjects: 30
Study: 20382717

Group type: EXPERIMENTAL
Intervention: Pleural ultrasound (PU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Chest radiograph (CXR)
Number of subjects: 44
Study: 18468831

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg single dose, intramuscular)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 15816572

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3 microg kg(‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study: 12020525

Group type: EXPERIMENTAL
Intervention: Azithromycin (1.5 g total dose over 5 days)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Vitamin C (1.5 g total dose over 5 days)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 220

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Albuterol inhaler
Number of subjects: 220
Study: 10335749

Group type: EXPERIMENTAL
Intervention: Standard error of measurement (SEM) applied to the Chronic Heart Failure Questionnaire (CHQ)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Standard error of measurement (SEM) applied to the SF-36
Number of subjects: 605
Study: 8949472

Group type: EXPERIMENTAL
Intervention: 1-day skills training for technical clinical skills
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Written test administered 1 month before and directly after the training
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Performance-based test
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Knowledge test score
Number of subjects: 71
Study: 1718723

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation (MS) delivered 200 msec before S1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation (MS) delivered simultaneously to and 20 msec after S1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation (MS) delivered 200 msec after S1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scalp stimulation of restricted scalp positions contralateral to the finger stimulated
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low intensities of finger stimulation and high intensities of MS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Absence of motor evoked responses in a peripheral hand muscle
Number of subjects: 8
Study: 29453751

Group type: EXPERIMENTAL
Intervention: Whole ewe's milk yogurt (EW, 5.8% fat)
Number of subjects: 30